Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 368 across all filing types
Latest filing 2025-01-17 Report Publication Anno…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location (YouTube), and purpose of the event. Since it is an announcement of an event rather than the presentation slides themselves or a full financial report, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2025-01-17 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, target audience, and purpose of the meeting. It is a short notification (under 5,000 characters) announcing the scheduling of an event and the future publication of IR materials, rather than the presentation itself. Therefore, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2025-01-17 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location, purpose, and target audience for the meeting. It does not contain the actual presentation slides or the full financial report, but rather serves as a notification of the event and the scheduled release of IR materials. Therefore, it is classified as a Report Publication Announcement (RPA) or a general regulatory filing regarding an event.
2025-01-17 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea used when an entity (in this case, the National Pension Service) crosses a significant ownership threshold in a publicly traded company (ABL Bio). This falls under the category of Major Shareholding Notification.
2025-01-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications, changes in special relationships, and stock collateral agreements. This falls under the 'Major Shareholding Notification' category.
2025-01-03 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report). It details changes to previously granted stock options, including adjustments to the number of shares and the list of recipients. This type of disclosure regarding stock option grants and their subsequent amendments falls under the category of capital structure and share-related changes, which is best classified as a Share Issue/Capital Change (SHA) filing in this taxonomy.
2024-12-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.